534 related articles for article (PubMed ID: 26557005)
1. Inflammation: A novel target of current therapies for hepatic encephalopathy in liver cirrhosis.
Luo M; Guo JY; Cao WK
World J Gastroenterol; 2015 Nov; 21(41):11815-24. PubMed ID: 26557005
[TBL] [Abstract][Full Text] [Related]
2. Potential targeted therapies for the inflammatory pathogenesis of hepatic encephalopathy.
Luo M; Liu H; Hu SJ; Bai FH
Clin Res Hepatol Gastroenterol; 2015 Dec; 39(6):665-73. PubMed ID: 26216028
[TBL] [Abstract][Full Text] [Related]
3. Optimal treatment of hepatic encephalopathy.
Waghray A; Waghray N; Kanna S; Mullen K
Minerva Gastroenterol Dietol; 2014 Mar; 60(1):55-70. PubMed ID: 24632768
[TBL] [Abstract][Full Text] [Related]
4. Inflammation and hepatic encephalopathy.
Coltart I; Tranah TH; Shawcross DL
Arch Biochem Biophys; 2013 Aug; 536(2):189-96. PubMed ID: 23583306
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis of hepatic encephalopathy in cirrhosis: the concept of synergism revisited.
Butterworth RF
Metab Brain Dis; 2016 Dec; 31(6):1211-1215. PubMed ID: 26521983
[TBL] [Abstract][Full Text] [Related]
6. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
[TBL] [Abstract][Full Text] [Related]
7. Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis.
Prakash RK; Kanna S; Mullen KD
Clin Ther; 2013 Sep; 35(9):1458-73. PubMed ID: 23972578
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
Irimia R; Trifan A
Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
[TBL] [Abstract][Full Text] [Related]
9. Effects of oral branched-chain amino acids on hepatic encephalopathy and outcome in patients with liver cirrhosis.
Kawaguchi T; Taniguchi E; Sata M
Nutr Clin Pract; 2013 Oct; 28(5):580-8. PubMed ID: 23945292
[TBL] [Abstract][Full Text] [Related]
10. Hepatic encephalopathy: pathophysiology and emerging therapies.
Sundaram V; Shaikh OS
Med Clin North Am; 2009 Jul; 93(4):819-36, vii. PubMed ID: 19577116
[TBL] [Abstract][Full Text] [Related]
11. Hepatic Encephalopathy: Pharmacological Therapies Targeting Ammonia.
Rahimi RS; Rockey DC
Semin Liver Dis; 2016 Feb; 36(1):48-55. PubMed ID: 26870932
[TBL] [Abstract][Full Text] [Related]
12. Management of hepatic encephalopathy in patients with cirrhosis.
Wright G; Jalan R
Best Pract Res Clin Gastroenterol; 2007; 21(1):95-110. PubMed ID: 17223499
[TBL] [Abstract][Full Text] [Related]
13. Hepatic encephalopathy: pathophysiology and advances in therapy.
Av SP
Trop Gastroenterol; 2007; 28(1):4-10. PubMed ID: 17896602
[TBL] [Abstract][Full Text] [Related]
14. Ammonia and the neutrophil in the pathogenesis of hepatic encephalopathy in cirrhosis.
Shawcross DL; Shabbir SS; Taylor NJ; Hughes RD
Hepatology; 2010 Mar; 51(3):1062-9. PubMed ID: 19890967
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with current standards of care.
Bohra A; Worland T; Hui S; Terbah R; Farrell A; Robertson M
World J Gastroenterol; 2020 May; 26(18):2221-2231. PubMed ID: 32476788
[TBL] [Abstract][Full Text] [Related]
16. Pharmacotherapy of hepatic encephalopathy in cirrhosis.
Romero-Gómez M
Expert Opin Pharmacother; 2010 Jun; 11(8):1317-27. PubMed ID: 20384539
[TBL] [Abstract][Full Text] [Related]
17. Pathophysiology, diagnosis, and management of hepatic encephalopathy.
Sheasgreen C; Lu L; Patel A
Inflammopharmacology; 2014 Dec; 22(6):319-26. PubMed ID: 25300964
[TBL] [Abstract][Full Text] [Related]
18. Serum endotoxin, inflammatory mediators, and magnetic resonance spectroscopy before and after treatment in patients with minimal hepatic encephalopathy.
Jain L; Sharma BC; Srivastava S; Puri SK; Sharma P; Sarin S
J Gastroenterol Hepatol; 2013 Jul; 28(7):1187-93. PubMed ID: 23425082
[TBL] [Abstract][Full Text] [Related]
19. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity.
Kaji K; Takaya H; Saikawa S; Furukawa M; Sato S; Kawaratani H; Kitade M; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
World J Gastroenterol; 2017 Dec; 23(47):8355-8366. PubMed ID: 29307995
[TBL] [Abstract][Full Text] [Related]
20. [Pathogenesis and treatment of hepatic encephalopathy].
Murawaki Y; Kawasaki H
Nihon Rinsho; 1994 Jan; 52(1):110-8. PubMed ID: 8114279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
